Cognition Therapeutics, Inc
Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on small-molecule therapies for age-related degenerative diseases of the central nervous system and retina. Its lead program, zervimesine (CT1812), is being developed to target the sigma-2 receptor complex and reduce the toxicity of amyloid beta oligomers, with the company positioning the drug for diseases such as dementia with Lewy bodies, Alzheimer’s disease, and geographic atrophy. The business is still in development mode, so it does not yet generate product revenue and depends on external financing, grants, and potential partnerships to fund research and clinical trials. Its value proposition is tied to whether zervimesine can show disease-modifying benefit in late-stage studies and ultimately secure regulatory approval.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDevelopment of zervimesine (CT1812) for neurodegenerative and retinal diseases.
Patient access programs and trial-related support for eligible DLB participants.
Discovery-stage work on additional sigma-2 receptor-based therapeutics.
Customers
Cognition does not currently sell approved products to commercial end customers; its near-term “customers” are primarily clinical trial participants, investigators, and trial sites that enroll patients into its studies. The company’s lead program is aimed at patients with dementia with Lewy bodies, Alzheimer’s disease, and related age-related degenerative disorders, where unmet medical need is high and current treatment options are limited. In the expanded access program, eligible U.S. patients with mild-to-moderate DLB who completed the Phase 2 study or meet program criteria can receive zervimesine outside a standard trial setting. Longer term, if approved, the company would need to serve neurologists, memory clinics, retina specialists, and potentially commercialization partners that would help bring the therapy to market.
Patients with DLB, Alzheimer’s disease, or related disorders who enroll in studies to receive zervimesine and generate efficacy/safety data.
Hospitals and specialty centers that recruit, dose, monitor, and assess patients in Cognition-sponsored trials.
Eligible DLB patients in the U.S. who receive daily oral zervimesine through the philanthropic-funded access program.
Neurologists, memory clinics, and specialty providers that would use the drug if it gains approval.
Potential third parties for ex-U.S. development, licensing, or commercialization if the company seeks to reduce go-to-market burden.
Strategy
Cognition’s core strategy is to advance zervimesine through clinical development and use the data package to support regulatory discussions with the FDA. The company is focusing on diseases with limited treatment options, which increases the potential clinical and commercial value if the drug demonstrates meaningful benefit. It is also preserving capital by outsourcing manufacturing, packaging, labeling, storage, and distribution rather than building internal facilities. Because it has no product sales yet, the company must continue raising capital, pursuing grants, and potentially forming partnerships to fund the next stages of development and eventual commercialization.
Regulatory approval depends on translating Phase 2 signals into a larger confirmatory program acceptable to the FDA.
The company needs continued efficacy and safety evidence to support differentiation and future partnering.
As a clinical-stage company with no product revenue, cash efficiency is essential to fund trials and regulatory work.
The company will need substantial additional capital before any commercial revenue is available.
Geography
Cognition is headquartered in the United States and its current operating footprint is centered on U.S.-based clinical development. The company disclosed eight U.S. sites for the expanded access program, all of which were active in the SHIMMER study, underscoring that its near-term execution is concentrated in domestic trial infrastructure. It also states that it may seek collaborations to commercialize zervimesine outside the United States, which suggests future geographic expansion could depend on partnerships rather than owned international operations. Because it does not own manufacturing facilities, its geographic exposure also includes third-party manufacturing and supply chains that may be located outside its headquarters market.
Risks
Cognition faces the classic risks of a clinical-stage biotech: its lead asset may fail to show sufficient efficacy, safety, or durability in larger trials, which would materially reduce the value of the pipeline. The company is also highly dependent on external capital because it has no product sales and expects continued losses until approval, so financing conditions directly affect its ability to keep developing zervimesine. Regulatory risk is meaningful because FDA review timing, staffing, and policy changes can delay or complicate development and approval. In addition, the company relies on third-party CROs and CMOs, so operational disruptions, manufacturing delays, or supply issues could affect trial execution and future launch readiness.
- Clinical development failure for zervimesineImpact: Critical
The company’s value depends heavily on one lead asset, and late-stage trials may not confirm efficacy or safety seen in Phase 2.
Exposure: Lead program and pipeline valuation
- Dependence on external financingImpact: HighLikelihood: High
The company expects significant losses and needs substantial additional funding before any product revenue is possible.
Exposure: Liquidity and operating continuity
- FDA and government funding disruptionImpact: HighLikelihood: Medium
Delays or staffing constraints at the FDA can slow review, approval, or guidance on the Phase 3 program.
Exposure: Regulatory timeline
- Third-party manufacturing and CRO dependenceImpact: Medium
The company does not own manufacturing facilities and relies on vendors for trial supply and future commercial production.
Exposure: Trial execution and launch readiness
- Safety/tolerability concernsImpact: Medium
Observed treatment-emergent liver function test elevations could become more important as exposure expands.
Exposure: Clinical program and labeling risk
Accounting
Judgemental itemsTrial and manufacturing costs are recognized as services are received, so estimates for CRO/CMO work can move quarterly expenses.
Impact: Affects operating loss and comparability across periods
Non-dilutive funding such as NIA grants may be recognized separately from operating expenses and can reduce net loss.
Impact: Affects other income and reported burn rate
Equity awards to employees and executives are a meaningful cost for a development-stage company.
Impact: Affects G&A and total operating expenses
The office lease in Purchase, New York creates right-of-use asset and lease liability accounting under standard lease rules.
Impact: Affects balance sheet leverage and occupancy expense
Recent offerings included warrants and placement fees that require careful equity classification and dilution analysis.
Impact: Affects share count, equity, and per-share valuation
Similar listed companies
Publicly listed companies with a comparable business focus.
Alpha Cognition Inc.
ACOG · Biological Products, (No Diagnostic Substances)
BioVie Inc
BIVIW · Pharmaceutical Preparations
CervoMed Inc.
CRVO · Pharmaceutical Preparations
Denali Therapeutics Inc.
DNLI · Biological Products, (No Diagnostic Substances)
Denali Therapeutics is a clinical-stage biopharmaceutical company developing barrier-crossing therapeutics for neurodegenerative and lysosomal storage diseases.
Coya Therapeutics, Inc.
COYA · Pharmaceutical Preparations
Anavex Life Sciences Corp
AVXL · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026